Skip to main content

Table 2 Overview of 1st- and 2nd-line treatments during the study period, mRCC patients, Estonia 2004–2012

From: Changes in therapy and survival of metastatic renal cell carcinoma in Estonia

 2004–2007200820092010201120122008–20122004–2012
First line treatment1372650475862243380
Immunotherapy INFa (%)137 (100)24 (92)24 (48)2 (4)2 (3)1 (2)53 (22)207 (55)
Targeted therapy (%)0 (0)2 (8)26 (52)45 (96)56 (97)61 (98)190 (78)190 (50)
INFa+Bevacizumab0171714125151 (13)
Sunitinib0016263842122122 (32)
Sorafenib01112055 (1)
Temsirolimus00212499 (2)
Pazopanib00000333 (1)
Second line treatment41521232418101105
Immunotherapy INFa (%)0 (0)0 (0)0 (0)0 (0)0 (0)1 (6)1 (1)1 (1)
Targeted therapy (%)4 (100)15 (100)21 (100)23 (100)24 (100)17 (94)100 (99)104 (99)
INFa+Bevacizumab00012477 (7)
Sunitinib0023711313 (12)
Sorafenib215181712127476 (72)
Temsirolimus00121044 (4)
Pazopanib20000002 (2)
Everolimus00002022 (2)